Amniotic Membrane for Eye Treatment and Healing

Amniotic membrane, the thin tissue that lines the innermost layer of the human placenta, has become one of the most versatile biological tools in eye care. Its ability to reduce inflammation, promote healing, and limit scarring makes it useful across a surprising range of conditions, from chemical burns and chronic dry eye to rare pediatric diseases that threaten vision. The membrane works partly because it is loaded with growth factors and structural proteins that the eye’s surface recognizes and responds to, and partly because it actively damps down the immune responses that cause so much collateral damage after an injury. How it is delivered, preserved, and applied varies widely depending on the problem being treated, and the evidence behind each use is stronger for some conditions than others.

Why a Placental Tissue Works on the Eye

The cornea and the amniotic membrane share something in common: both are transparent or translucent tissues that rely on a delicate basement membrane to support epithelial cells. That structural similarity is not a coincidence of convenience. The amniotic membrane’s basement membrane actively helps corneal epithelial cells migrate and adhere, essentially providing scaffolding that guides new cells into place over a wound.¹ It also preserves a rich collection of extracellular matrix proteins, including collagens, glycoproteins like laminin and vitronectin, and growth factors such as epidermal growth factor (EGF) and transforming growth factor-beta, all of which play roles in tissue regeneration.²

Laboratory analysis of amniotic membrane preparations has identified at least four key growth factors: hepatocyte growth factor (HGF), EGF, keratinocyte growth factor, and basic fibroblast growth factor. HGF was the most abundant by a wide margin, followed by EGF.³ These are not inert building blocks sitting passively on the eye. They actively signal to cells in the wounded tissue, telling them to proliferate, migrate, and rebuild.

Calming Inflammation and Preventing Scars

An injured eye often does more damage to itself through inflammation than the original insult caused. Neutrophils flood the wound and release destructive enzymes, and fibroblasts can transform into scar-forming cells that cloud the cornea permanently. Amniotic membrane fights both problems. Stem cells within the membrane secrete anti-inflammatory molecules, including a protein called TSG-6 that directly reduces the release of neutrophil extracellular traps, one of the key drivers of tissue destruction after corneal injury.⁴

On the scarring side, the membrane contains factors that suppress a signaling pathway in fibroblasts, preventing them from differentiating into myofibroblasts and laying down excessive scar tissue.⁵ By breaking the cycle of chronic inflammation, the membrane lets wound healing actually progress rather than stalling out in an endless loop of tissue damage and inflammatory response. This dual action, anti-inflammatory and anti-fibrotic, is what makes it so broadly applicable across different eye conditions.

Chemical and Thermal Burns

Acute chemical burns to the eye are emergencies, and amniotic membrane transplantation has become a standard adjunct to the immediate wash-out and medical therapy. In one series of 15 eyes with chemical burns, all patients experienced immediate pain relief after the membrane was applied, and about 60% achieved complete epithelial healing within one to four weeks. Vision improved in roughly two-thirds of the treated eyes, with better outcomes in moderate burns than in the most severe cases.⁶ Earlier work confirmed that in mild to moderate burns, the membrane alone can restore both the corneal and conjunctival surfaces, promoting re-epithelialization and reducing the inflammation that leads to late-stage scarring.⁷

The evidence does have a ceiling. A report by the American Academy of Ophthalmology concluded that while amniotic membrane grafting can speed up re-epithelialization after moderate burns, the same studies did not show additional improvement in re-epithelialization for severe burns, nor did they demonstrate gains in visual acuity or corneal clarity for either severity level when used as an add-on to standard medical therapy.⁸ So while the membrane clearly helps moderate injuries heal faster and more comfortably, it is not a magic fix for the worst burns, where deeper tissue destruction outstrips what a surface-applied biological bandage can address.

Persistent Corneal Epithelial Defects

Sometimes the surface of the cornea simply refuses to heal. These persistent epithelial defects can follow surgery, infection, or neurotrophic disease, and they put the eye at risk of ulceration and perforation. Amniotic membrane transplantation is one of the main interventions when conventional treatments like lubricants and therapeutic contact lenses fail. A comparative study found that amniotic membrane-treated eyes healed in a median of about 10 days, roughly half the time of the alternative procedure (tarsorrhaphy, in which the eyelids are partially sewn shut).⁹

Longer follow-up data from a separate trial showed healing rates of about 86% for amniotic membrane transplantation versus 70% for tarsorrhaphy at six months, though the difference did not reach statistical significance given the study size.¹⁰ Clinically, the membrane has a practical advantage: patients can still see during treatment, unlike with tarsorrhaphy, where stitching the lids shut blocks vision in the affected eye.

Severe Dry Eye Disease

For people with moderate to severe dry eye that has not responded to drops, gels, and prescription anti-inflammatory medications, amniotic membrane treatment has emerged as a meaningful option. The DREAM study placed cryopreserved amniotic membrane on the eyes of 84 patients who had failed maximal medical therapy. After an average of about five days of wear, roughly 88% showed an improved ocular surface, with severity scores dropping sharply at one week and remaining low through at least three months.¹¹

Another study estimated that approximately five days of membrane placement produced an average of four months of symptom relief, along with reduced reliance on topical medications and measurable improvements in corneal staining and redness.¹² A more recent randomized trial using a dehydrated amniotic membrane delivered via a specialized bandage contact lens found a 65% reduction in symptom scores at six months, along with improvements in corneal nerve health and a decrease in inflammatory cell counts on the corneal surface.¹³ The nerve recovery piece is particularly interesting: damaged corneal nerves are a major driver of chronic dry eye symptoms, and the membrane appears to support their regeneration in ways that traditional drops do not.

Stevens-Johnson Syndrome

Stevens-Johnson syndrome (SJS) and its more severe form, toxic epidermal necrolysis, are rare but devastating drug reactions that can destroy the ocular surface within days. The eyes become acutely inflamed, and without intervention, scarring can fuse the eyelids to the eyeball, obliterate the tear film, and cause permanent blindness. Early application of amniotic membrane is now considered essential to preserve long-term ocular surface integrity in these cases.¹⁴

Long-term outcome data show that when amniotic membrane is placed during the acute phase of SJS, it can prevent the severe vision loss that otherwise frequently follows.¹⁵ The clinical consensus has shifted toward a low threshold for grafting in any SJS patient with ocular involvement, since the window for effective intervention is narrow and the consequences of waiting are often irreversible.¹⁶

Pterygium Surgery

A pterygium is a fleshy, triangular growth that extends from the white of the eye onto the cornea, and surgery to remove it has a notorious problem: recurrence. Amniotic membrane is used to cover the bare area left after the pterygium is excised, serving as both a biological bandage and a barrier to regrowth. In one series of 50 eyes, only one case (2%) developed a recurrence after membrane transplantation.¹⁷

Head-to-head comparisons with conjunctival autografting, the other common approach, have produced mixed results. One trial reported recurrence rates of about 35% with the amniotic membrane versus 25% with conjunctival autograft, with no statistically significant difference.¹⁸ Another found recurrence rates of roughly 7% and 3% respectively, again without a significant difference, but noted that the amniotic membrane group had somewhat higher postoperative inflammation in the first months.¹⁹ In practice, the membrane is often chosen when the surgeon wants to preserve conjunctival tissue for possible future procedures (such as glaucoma surgery), or when the pterygium is large and a conjunctival graft would not cover the defect well.

Glaucoma Surgery Repairs

Amniotic membrane has found a niche in managing complications of glaucoma surgery rather than as a primary glaucoma treatment. Tube shunt implants can erode through the overlying tissue over time, exposing the tube and creating a pathway for infection. In a series of these cases, a double layer of amniotic membrane achieved lasting closure of the conjunctival defect in every eye treated.²⁰

For leaking filtration blebs, the picture is less favorable. A randomized trial comparing amniotic membrane transplantation with standard conjunctival advancement for bleb repair found similar long-term intraocular pressure control between the two groups over a median follow-up of nearly seven years. However, there were seven failures in the membrane group versus four in the conjunctival advancement group, and the trend, while not statistically significant, favored conjunctival advancement.²¹ An earlier analysis of the same trial, with shorter follow-up, was more direct: it concluded that amniotic membrane transplantation does not offer an alternative to conjunctival advancement for bleb leak repair.²² The membrane works well for covering exposed hardware but is not the best choice for every glaucoma surgical complication.

How It Gets to the Eye

The original technique involves suturing the membrane directly onto the eye under local or general anesthesia. For larger defects, an overlay graft about 12 to 14 mm in diameter can cover the entire corneal and perilimbal surface. For smaller, localized defects, an inlay graft is cut to size and sutured to the edges of the wound.²³ This approach is still widely used for surgical indications, but it requires an operating room and adds the discomfort and cost of sutures.

The shift toward sutureless delivery has been significant. Self-retained devices, like a ring system that holds the membrane against the eye under a bandage contact lens, can be placed in the office in minutes. One study of such a device across multiple conditions found complete or partial success in 44% to 80% of eyes depending on the indication, though about 17% of patients experienced discomfort from the device itself.²⁴ Sutureless delivery has opened the door to treating conditions like dry eye and mild epithelial defects that would never have justified a trip to the operating room.

Preservation Matters More Than You Might Think

Not all amniotic membrane products are equivalent, and the method used to preserve the tissue substantially affects what biologically active material actually reaches the eye. Cryopreservation, the most established method, retains the membrane’s structure but loses a significant share of its growth factors. One study found that cryopreserved membrane retained only about 13% of its total EGF, with over half leaching out during the very first wash. By contrast, drying the membrane, especially with sugar-based stabilizers like trehalose or raffinose, retained 83% to 88% of EGF.²⁵

This does not necessarily mean dried membrane is always superior in practice; cryopreserved membrane has the longest clinical track record and has demonstrated efficacy in dozens of trials. But it does suggest that some of the benefit patients get from the membrane comes from its structural scaffolding rather than from its growth factor payload alone, and it means that newer dehydrated products may deliver more biological activity per application.

Amniotic Membrane Eye Drops

An emerging alternative to placing tissue on the eye is extracting the active components and delivering them as eye drops. Amniotic membrane extract drops have already been used clinically for dry eye and chemical burns.²⁶ In an experimental alkaline burn model, topical application of amniotic membrane extract at clinically relevant doses resulted in significantly less corneal opacity, less vascularization, less stromal scarring, and less inflammatory cell infiltration than either membrane transplantation or no treatment.²⁷ If these results translate to human clinical practice, drops could eventually offer a less invasive, easier-to-administer alternative to grafting in some situations. Drops can be applied at home, do not require a device or ring on the eye, and could theoretically be dosed more frequently or over longer treatment periods.

Safety and Complications

Amniotic membrane is one of the better-tolerated biological tissues used in medicine. It is immunologically privileged, meaning the body rarely mounts a rejection response against it. Serious complications are uncommon. A systematic review of sutureless membrane use across over 500 eyes found sterile infiltrate in fewer than 2% of eyes, corneal perforation in 0.6%, and worsened epithelial defects from device trauma in 0.4%. The most common adverse effects were mild pain (about 3% of eyes) and displacement of the membrane or retention ring (under 2%).²⁸ In surgically sutured grafts, graft retraction and graft rejection have been reported in about 3% of cases each in one series.²⁹

On the regulatory side, amniotic membrane products in the United States must meet FDA standards under human tissue product regulations, which cover donor screening, tissue processing, and labeling.³⁰ Donors are screened for infectious diseases, and the tissue undergoes processing to reduce microbial risk. Because the membrane is avascular and immunologically quiet, the infection and rejection risks that hang over many other tissue transplants are much lower here.

Costs and Access

Amniotic membrane treatment is not cheap, but the economics are more nuanced than the sticker price suggests. A cost-utility analysis comparing cryopreserved amniotic membrane with topical cyclosporine for moderate to severe dry eye found that when indirect costs like lost productivity were included, the membrane was actually the less expensive option over a year, despite higher direct medical costs. Monte Carlo simulation in the same study found the membrane was the less costly and more effective alternative over 90% of the time.³¹ Looking at direct costs alone, though, cyclosporine was cheaper: roughly $4,100 versus $10,300 over a year.

Usage has grown enormously. In the Medicare population, charges for sutureless amniotic membrane grafts jumped from $3.5 million in 2011 to $95.6 million in 2020. Dry eye alone accounted for a surge from $250,000 to over $41 million in that period.³² That explosive growth has prompted scrutiny from insurers and policymakers about appropriate use. Medicare does cover amniotic membrane grafting, but prior authorization requirements vary, and some private insurers have been slower to approve it for conditions like dry eye, where the evidence, while growing, is more recent.

Children and Amniotic Membrane

Pediatric use follows many of the same principles as adult use, but the stakes and logistics differ. Children cannot cooperate with office-based procedures, so membrane placement often requires general anesthesia. A review of 48 pediatric cases found that about two-thirds received amniotic membrane for Stevens-Johnson syndrome, with a clinical success rate of 94%. The remaining third had other conditions including difficult corneal defects and conjunctival scarring after strabismus surgery, with an 80% success rate. No adverse effects related to the membrane were reported in either group.³³

A broader scoping review confirmed the membrane’s value as a biological bandage across various pediatric eye conditions, noting its ability to promote re-epithelialization, modulate inflammation, and improve healing outcomes.³⁴ In rare genetic conditions like recessive dystrophic epidermolysis bullosa, where the cornea can scar and opacify in childhood, amniotic membrane transplantation combined with superficial keratectomy has improved vision dramatically, with some children going from barely able to see at arm’s length to near-normal acuity, maintained over years of follow-up.³⁵

The Role in Limbal Stem Cell Support

The limbus is a narrow ring of tissue at the border of the cornea and the white of the eye, and it houses the stem cells responsible for continually renewing the corneal surface. When these stem cells are damaged or destroyed, as can happen with severe burns or chronic inflammatory disease, the cornea can no longer maintain a clear surface. Amniotic membrane has properties that support the growth of epithelial cells while controlling inflammation and scarring in this critical zone.³⁶ Clinically, the membrane serves two related purposes here: it can act as a substrate for culturing limbal stem cells in the laboratory before transplanting them back to the patient, and it can be placed directly on the eye to protect a damaged limbal region while residual stem cells attempt to repopulate.

This is an area where the membrane is part of a larger therapeutic strategy rather than a standalone cure. Patients with total limbal stem cell deficiency still need a source of new stem cells, whether from their other eye, a donor, or a cultured graft. But the membrane provides the environment those cells need to survive and expand once they arrive.